Connection

Co-Authors

This is a "connection" page, showing publications co-authored by EHAB Y HANNA and SHIRLEY YU SU.
Connection Strength

5.746
  1. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017 08; 39(8):1671-1679.
    View in: PubMed
    Score: 0.596
  2. Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: differentiation in diagnosis and treatment. Int Arch Otorhinolaryngol. 2014 Oct; 18(Suppl 2):S149-56.
    View in: PubMed
    Score: 0.495
  3. Endoscopic resection of sinonasal cancers. Curr Oncol Rep. 2014 Feb; 16(2):369.
    View in: PubMed
    Score: 0.473
  4. Neurocognitive Functioning of Patients with Sinonasal and Nasopharyngeal Cancers Treated With Multimodality Therapy. J Neurol Surg B Skull Base. 2024 Dec; 85(6):614-621.
    View in: PubMed
    Score: 0.231
  5. Prevalence of pituitary hormone dysfunction following radiotherapy for sinonasal and nasopharyngeal malignancies. Head Neck. 2023 10; 45(10):2525-2532.
    View in: PubMed
    Score: 0.228
  6. Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma. Otolaryngol Head Neck Surg. 2023 08; 169(2):435-440.
    View in: PubMed
    Score: 0.222
  7. Functional Outcomes and Quality of Life in Patients with Sinonasal, Nasopharyngeal, and Anterior Skull Base Tumors. Curr Oncol Rep. 2022 06; 24(6):775-781.
    View in: PubMed
    Score: 0.207
  8. Long-Term Outcomes of Olfactory Neuroblastoma: MD Anderson Cancer Center Experience and Review of the Literature. Laryngoscope. 2022 02; 132(2):290-297.
    View in: PubMed
    Score: 0.198
  9. Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. Cancer. 2021 06 01; 127(11):1788-1795.
    View in: PubMed
    Score: 0.192
  10. Clinical Implication of Diagnostic and Histopathologic Discrepancies in Sinonasal Malignancies. Laryngoscope. 2021 05; 131(5):E1468-E1475.
    View in: PubMed
    Score: 0.187
  11. Endoscopic resection of sinonasal malignancies. Head Neck. 2020 04; 42(4):645-652.
    View in: PubMed
    Score: 0.178
  12. Long-term quality of life after definitive treatment of sinonasal and nasopharyngeal malignancies. Laryngoscope. 2020 01; 130(1):86-93.
    View in: PubMed
    Score: 0.167
  13. Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. J Clin Oncol. 2019 02 20; 37(6):504-512.
    View in: PubMed
    Score: 0.166
  14. Prognostic factors and survival in adenoid cystic carcinoma of the sinonasal cavity. Head Neck. 2018 12; 40(12):2596-2605.
    View in: PubMed
    Score: 0.165
  15. Patterns of Treatment Failure in Patients with Sinonasal Mucosal Melanoma. Ann Surg Oncol. 2018 Jun; 25(6):1723-1729.
    View in: PubMed
    Score: 0.158
  16. Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb. Laryngoscope. 2018 06; 128(6):1274-1280.
    View in: PubMed
    Score: 0.154
  17. Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma. Cancer. 2018 02 01; 124(3):514-520.
    View in: PubMed
    Score: 0.153
  18. Role of Adjuvant Treatment in Sinonasal Mucosal Melanoma. J Neurol Surg B Skull Base. 2017 Dec; 78(6):512-518.
    View in: PubMed
    Score: 0.151
  19. Mutation status among patients with sinonasal mucosal melanoma and its impact on survival. Br J Cancer. 2017 Jun 06; 116(12):1564-1571.
    View in: PubMed
    Score: 0.148
  20. Impact of Previous Surgery and/or Radiation Therapy on Endoscopic Reconstruction Outcomes. Oper Neurosurg (Hagerstown). 2024 Aug 26.
    View in: PubMed
    Score: 0.061
  21. Orbital and periocular complications in patients with sinonasal tumours with orbital invasion. Br J Ophthalmol. 2024 02 21; 108(3):465-470.
    View in: PubMed
    Score: 0.059
  22. Does Time to Initiation of Adjuvant Radiotherapy Affect Reconstruction Outcomes after Endoscopic Resection of Skull Base Malignancies? J Neurol Surg B Skull Base. 2024 Oct; 85(5):445-457.
    View in: PubMed
    Score: 0.057
  23. Predictors of postoperative performance status after surgical management of infratemporal fossa malignancies. Neurosurg Rev. 2023 Jun 29; 46(1):157.
    View in: PubMed
    Score: 0.057
  24. Patient, Disease, and Treatment-Related Factors Affecting Progression-Free and Disease-Specific Survival in Recurrent Chondrosarcomas of the Skull Base. Oper Neurosurg (Hagerstown). 2023 01 01; 24(1):33-43.
    View in: PubMed
    Score: 0.054
  25. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Front Oncol. 2022; 12:1001150.
    View in: PubMed
    Score: 0.054
  26. Soft Tissue Sarcomas of the Head and Neck Region with Skull Base/Intracranial Invasion: Review of Surgical Outcomes and Multimodal Treatment Strategies: A Retrospective Case Series. Curr Oncol. 2022 09 14; 29(9):6540-6550.
    View in: PubMed
    Score: 0.054
  27. The impact of expanded endoscopic approaches on oncologic and functional outcomes for clival malignancies:a case series. J Neurooncol. 2022 Sep; 159(3):627-635.
    View in: PubMed
    Score: 0.053
  28. Impact of salvage surgery for recurrent sinonasal cancers with skull base and intracranial involvement. J Neurosurg. 2022 Oct 01; 137(4):961-968.
    View in: PubMed
    Score: 0.051
  29. The neurosurgical management of sinonasal malignancies involving the anterior skull base: a 28-year experience at The MD Anderson Cancer Center. J Neurosurg. 2022 Jun 01; 136(6):1583-1591.
    View in: PubMed
    Score: 0.050
  30. The effect of prior radiation on the success of ventral skull base reconstruction: A systematic review and meta-analysis. Head Neck. 2021 09; 43(9):2795-2806.
    View in: PubMed
    Score: 0.049
  31. Surgical Management of Skull Base Osteoradionecrosis in the Cancer Population - Treatment Outcomes and Predictors of Recurrence: A Case Series. Oper Neurosurg (Hagerstown). 2020 09 15; 19(4):364-374.
    View in: PubMed
    Score: 0.047
  32. Surgical management of carcinomas of the infratemporal fossa and skull base: patterns of failure and predictors of long-term outcomes. J Neurosurg. 2021 05 01; 134(5):1392-1398.
    View in: PubMed
    Score: 0.046
  33. Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. Head Neck. 2020 06; 42(6):1194-1201.
    View in: PubMed
    Score: 0.046
  34. Management of olfactory neuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma involving the skullbase. J Neurooncol. 2020 Dec; 150(3):367-375.
    View in: PubMed
    Score: 0.046
  35. Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. Radiother Oncol. 2020 07; 148:258-266.
    View in: PubMed
    Score: 0.046
  36. SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. Pract Radiat Oncol. 2020 Sep - Oct; 10(5):363-371.
    View in: PubMed
    Score: 0.045
  37. Surgical Management of Primary Skull Base Osteosarcomas: Impact of Margin Status and Patterns of Relapse. Neurosurgery. 2020 01 01; 86(1):E23-E32.
    View in: PubMed
    Score: 0.045
  38. A prospective evaluation of health-related quality of life after skull base re-irradiation. Head Neck. 2020 03; 42(3):485-497.
    View in: PubMed
    Score: 0.044
  39. Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. J Neurol Surg B Skull Base. 2020 Dec; 81(6):638-644.
    View in: PubMed
    Score: 0.043
  40. Endoscopic endonasal transpterygoid transnasopharyngeal management of petroclival chondrosarcomas without medial extension. J Neurosurg. 2019 07 01; 131(1):184-191.
    View in: PubMed
    Score: 0.040
  41. Site-Specific Considerations in the Surgical Management of Skull Base Chondrosarcomas. Oper Neurosurg (Hagerstown). 2018 06 01; 14(6):611-619.
    View in: PubMed
    Score: 0.040
  42. Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. J Neurosurg. 2019 03 01; 130(3):812-821.
    View in: PubMed
    Score: 0.040
  43. Impact of early access to multidisciplinary care on treatment outcomes in patients with skull base chordoma. Acta Neurochir (Wien). 2018 04; 160(4):731-740.
    View in: PubMed
    Score: 0.039
  44. Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. Head Neck. 2017 10; 39(10):2048-2056.
    View in: PubMed
    Score: 0.038
  45. Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. Head Neck. 2017 10; 39(10):2079-2087.
    View in: PubMed
    Score: 0.038
  46. The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):241-247.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.